Health technology major Royal Philips has introduced an updated version of its TissueMark computational pathology solution software at Euskalduna Conference Centre in Bilbao, Spain.
The new TissueMark version leverages artificial intelligence (AI) to support region of interest detection for molecular testing as well as assists research labs in enhancing the accuracy of tumour estimation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will also offer tumour sufficiency guidance for lung histology, lung cytology, colon and breast tissue samples along with whole slide images (WSI) of adenocarcinoma prostate tissue as well as high-grade serous carcinoma ovarian tissue.
Philips digital and computational pathology general manager Marlon Thompson said: “Using a microscope for tumour estimation is subjective and leads to high variability amongst pathologists.
“By digitising the tissue slide and analysing the image with robust computational software and intelligent algorithms, we can better support pathologists’ workflows and help labs enhance quality and reliability while reducing costs by limiting the number of molecular tests performed with insufficient tumour content.”
In addition, the company aims to support pathologists’ workflows by digitising the tissue slide and uses computational software and intelligent algorithms to analyse the image.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis will assist labs to improve quality and reliability as well as reduce costs by limiting the number of molecular tests performed with insufficient tumour content.
Earlier this year, the technology company unveiled its AI platform for healthcare.
